CNCE Concert Pharmaceuticals Inc.

10.46
+0.19  (+2%)
Previous Close 10.27
Open 10.34
Price To Book 1.86
Market Cap 248,946,180
Shares 23,799,826
Volume 65,781
Short Ratio
Av. Daily Volume 207,591

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 8mg data released November 12, 2018 - primary endpoint met. 12mg data due 3Q 2019.
CTP-543
Alopecia areata
Phase 3 data due by year-end 2019.
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
CTP-499
Diabetic Kidney Disease
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 1 data presented at ASCP May 30, 2019.
CTP-692 (single dose)
Schizophrenia
Phase 2 trial to be completed 4Q 2019.
CTP-543 - open label (Once-Daily vs. Twice-Daily)
Alopecia areata
Phase 2 trial to be initiated 4Q 2019. Phase 1 data to be presented at the ECNP Annual Congress, September 7-10, 2019.
CTP-692
Schizophrenia
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis
Phase 2 data due 1H 2020.
CTP-543 - open label (12 mg twice-daily or 24 mg once-daily)
Alopecia areata

Latest News

  1. What You Must Know About Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Beta Value
  2. Concert Pharmaceuticals, Inc. (CNCE) Q2 2019 Earnings Call Transcript
  3. Edited Transcript of CNCE earnings conference call or presentation 1-Aug-19 12:30pm GMT
  4. Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates
  5. Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019
  6. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Increased Their Holdings
  7. Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
  8. Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
  9. Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
  10. Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT
  11. Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
  12. Concert Pharmaceuticals to Present at Upcoming Investor Conferences
  13. Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You
  14. Concert: 1Q Earnings Snapshot
  15. Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
  16. Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors
  17. Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline
  18. Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019
  19. Concert Pharma Initiates Early-Stage Schizophrenia Study